Boundless Bio, Inc. (BOLD)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Ms. Jessica Oien J.D.
|
President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary | -- | -- | 1971 |
|
Mr. David Hinkle
|
Senior VP of Finance, Controller & Corporate Treasurer | -- | -- | 1962 |
|
Ms. Meredith Wesley
|
Chief Human Resources Officer | -- | -- | -- |
Boundless Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 28
Description
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
October 26, 2026 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
